文献速递肾小球疾病

原发性膜性肾病患者调节性B细胞减少且与疾病活动相关

Regulatory B Cells Are Reduced and Correlate With Disease Activity in Primary Membranous Nephropathy.
PubMed 文献 · Kidney Int Rep · 2020-03-30

患者调节性B细胞比例显著低于健康对照(P=0.0007),治疗后两类细胞均显著升高,且18个月缓解者调节性B细胞升高更明显。

要点

  • 原发性膜性肾病患者调节性B细胞比例显著低于健康对照。
  • 环磷酰胺联合激素治疗8个月后调节性T细胞和B细胞均显著升高。
  • 18个月达缓解者调节性B细胞升高与临床活动改善相关。

核心结论

  • 原发性膜性肾病患者调节性B细胞比例低于健康对照,且与疾病临床活动相关。

研究设计与样本

  • 在治疗前及治疗6个月和8个月(洗脱2个月)采集血样,用流式细胞术检测调节性T细胞和调节性B细胞。

主要发现

  • 患者调节性T细胞比例低于健康对照(P=0.07),调节性B细胞比例显著低于健康对照(P=0.0007)。
  • 与基线相比,治疗8个月时调节性B细胞(P=0.001)和调节性T细胞(P=0.02)均显著升高。
  • 18个月时达到缓解的患者,第8个月调节性T细胞(P=0.05)和调节性B细胞(P=0.0001)较基线升高。

临床怎么用

  • 调节性B细胞比例可能作为原发性膜性肾病疾病活动和治疗反应的监测指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Primary membranous nephropathy (PMN) is an autoimmune disease. Both T-regulatory cells (TREGs) and B-regulatory cells (BREGs) are decreased in patients with autoimmune disease. We evaluated the TREG and BREG population in patients of PMN treated with cyclical cyclophosphamide and steroid therapy (cCYC/GC). METHODS: Twenty-four patients with PMN resistant to a restrictive strategy and treated with cCYC/GC therapy and 10 healthy controls were enrolled. The proteinuria, serum creatinine, and serum albumin were tested at monthly intervals and blood samples were collected before starting cCYC/GC and at 6 and 8 (2 months wash out) months of therapy. The peripheral blood mononuclear cells (PBMCs) after staining with fluorochrome-conjugated antibodies were then subjected to flow cytometric analysis for detection of TREGs (CD3+CD4+CD25hiCD127loFoxP3+) and BREGs (CD19+CD5+CD1dhiIL10+). TREGs and BREGs are presented as the percentage of T and B cells, respectively. Cases with remission at month 18 were classified as responders, and those without any remission as nonresponders. RESULTS: Patients with PMN had a lower percentage of TREGs (P = 0.07) and BREGs compared with healthy controls (P = 0.0007). As compared with baseline, there was a significant increase in both BREGs (P = 0.001) and TREGs (P = 0.02) with the treatment (8 months). Patients who responded to therapy by 18 months had an increase in TREG (P = 0.05) and BREG (P = 0.0001) at month 8 compared with baseline. CONCLUSION: As compared with healthy controls, patients with PMN displayed a lower percentage of BREGs. Both TREGs and BREGs significantly improved with disease-specific therapy. BREGs had an association with clinical activity.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Ramachandran R, Kaundal U, Girimaji N, et al. Regulatory B Cells Are Reduced and Correlate With Disease Activity in Primary Membranous Nephropathy. Kidney Int Rep. 2020. PMID: 32518869. doi:10.1016/j.ekir.2020.03.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。